Shield Therapeutics Share Discussion Threads

[parob] 20/5/2021 07:24

STX tipped in today's Shares Magazine.hTTps://twitter.com/purestockfacts/status/1395240259760398339?s=21Buy Shield Therapeutics as it stands on cusp of US breakthrough.

[daveboy19] 19/5/2021 13:43

Not sure about that, powerp2 - DNL have a royalty/sales agreement with Eton in place for a while and we have not heard a thing about it thus far, and their CEO is a bit more savvy.

[powerp2] 19/5/2021 13:16

I wonder just how good European sales are. If Norgine are tearing up trees I'm sure we would have been told wouldn't we?

[78steve] 19/5/2021 13:14

The drug is being used and selling in europe just a case of replicating it in US so it's a test of marketting/selling now. I suppose recently appointed neds can help in this regard. Dyor

[stevee1234] 19/5/2021 11:43

Guys, my guess is the rns's are being choreographed this week and the update will be released shortly.

[daveboy19] 19/5/2021 11:12

Hope so, also - but he broke three timelines last year.

[oapknob1] 19/5/2021 10:40

If he would update when he says he will that would be good.

[shandypants2] 19/5/2021 09:46

ffrin - he may not be CEO material but i notice in the 2020 accounts he has just been awarded 625k share options at 1.5p. Not bad for a year in which he failed to achieve his main objective - the US commercial deal.
Also previous CEO who 'resigned' in April 2020 was paid an extra £327k when he left, c 1 year's extra salary. This is on top of earning over £500k for the last 2 years and as CEO was ultimately responsible for the H2H debacle. STX need to stop rewarding failure

[frrinvest] 19/5/2021 09:36

We all know TW is a bit of a lose canon and not a CEO material. His communication and presentation skills are below average for a CEO. Saying this, I feel confident Accrufer (R) will be launched by end of Q2. They can't afford any more mishaps and evidence so far points to STX achieving this goal.

[oapknob1] 19/5/2021 08:08

Tim Watts, CEO of Shield Therapeutics plc, said:MID MAY !"I am excited about the prospects for Accrufer(R), which we remain on track to launch in the US by the end of June 2021, and we will update shareholders in mid-May as to our progress towards the US launch."

[best1467] 18/5/2021 12:44

Nice to confirmation from from a Peer Reviewed journal into longterm benefits versus IV which surely as to be the big sales driver

[purchaseatthetop] 18/5/2021 11:03

just added at 55.48p. quite surprised by the price and pleased. thought I would have to pay nearer 56.5p.

[parob] 18/5/2021 07:40

hTTps://twitter.com/financefunky/status/1394541631433584640?s=21This paper from 2015 (prior to development of Accrufer/Ferracru) details options for treatment for iron deficiency in patients with IBD.Note all the main listed limitations of oral therapy and IV therapy are solved today by Shield's product.See tweet by Funky Finance.

[amaretto1] 18/5/2021 07:38

It's an absolute no brainer, why on earth would you not take this route of treatment from STX for iron deficiency.Once this starts hitting market share in USA .... STX will be taken out.And just look at the recent new recruits to the team at STX..... :-)

[parob] 18/5/2021 07:34

Lots more news due too.

[purchaseatthetop] 18/5/2021 07:30

60p today (PATTtrueforecast)

[purchaseatthetop] 18/5/2021 07:25

parob...and as far as I understand it avoid the time, cost and discomfort of IV treatment. Really good

[parob] 18/5/2021 07:23

The safety profile of each treatment was consistent with previous studies and mirrors my daily clinical practice. Thus, ferric maltol offers a simple, well tolerated and cost-effective long-term treatment solution of chronic IDA in patients with IBD.

[purchaseatthetop] 18/5/2021 07:15

Wow...another day another RNS.

[alancapone] 18/5/2021 07:07

Shield Therapeutics PLC

18 May 2021

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

AEGIS-H2H study results published in Inflammatory Bowel Diseases

Study demonstrates long-term effectiveness of ferric maltol compared to intravenous iron

London, UK, 18 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), notes the recent publication in the journal Inflammatory Bowel Diseases of positive long-term results from a study comparing the effectiveness of ferric maltol 30 mg bid with intravenous (IV) iron (ferric carboxymaltose given according to each centre's standard practice) over 52 weeks. The primary endpoint was haemoglobin responder rate (>=2 g/dL increase or normalization) at week 12, with a 20% noninferiority limit in the intent-to-treat and per protocol populations.

The open label Phase 3B study included adults with non-severe active IBD and iron-deficiency anaemia (IDA) and who also had serum ferritin levels below 30 g/L or ferritin levels below 100 g/L and transferrin saturation below 20%. The report of this first comparative trial, reflecting real-world conditions in patients with quiescent or mild to moderate IBD and mild to severe IDA, concluded that both oral ferric maltol and standard regimens of IV ferric carboxymaltose achieved clinically meaningful increases in Hb over 12 weeks of treatment, although ferric maltol did not meet the prespecified noninferiority margin vs IV iron. Over the longer term, ferric maltol showed comparable efficacy in maintaining Hb improvements and increasing ferritin up to week 52, consistent with IV iron. The safety profile of each treatment was consistent with previous studies.

The publication can be found at

hxxps://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izab073/6275616

The lead author, Dr Stephanie Howaldt stated: " Ferric maltol showed long-term comparable effectiveness in maintaining Hb improvements and increasing ferritin up to week 52, consistent with IV iron. The safety profile of each treatment was consistent with previous studies and mirrors my daily clinical practice. Thus, ferric maltol offers a simple, well tolerated and cost-effective long-term treatment solution of chronic IDA in patients with IBD. "

[purchaseatthetop] 18/5/2021 06:51

Thanks for that Parob. Adds to the story and interesting that he mentioned NASDAQ.

[parob] 17/5/2021 20:51

An update video on the back of today's news/Vox interview from Funky Finance: hTTps://www.youtube.com/watch?v=RAIIdXwhRog

[donaferentes] 17/5/2021 17:58

Otcqx price is $0.716 mid price just under 51p with an 8% spread on EMS of 10,000, as I write. Doesn't mention volume traded.

[frrinvest] 17/5/2021 17:34

137.9K buy @56p showing late trade.

[purchaseatthetop] 17/5/2021 17:25

78steve..the volumes in the USA will be so low that IMO it is not a true/relevant market at the moment. I would not worry about it at the moment.